Biologic Winrevair Wins FDA Approval for Treatment of PAH
The injectable activin signaling inhibitor is the first of this class to be approved by the FDA and is meant to be given every 3 weeks.
The injectable activin signaling inhibitor is the first of this class to be approved by the FDA and is meant to be given every 3 weeks.
DETROIT, April 27, 2024 — At an event today featuring the NFL’s Smart Heart Sports Coalition, Buffalo Bills Safety Damar Hamlin’s Chasing M’s Foundation, the…
Congratulations to all facilities that recently earned an ACC Accreditation!
Automated AI-generated measurements combined with annotated CT images can improve treatment planning and help referring physicians and patients better understand their disease, explained Sarah Jane…
Alison Bailey, MD, co-chair of the business of cardiology sessions at ACC.24, emphasized that reimbursement cuts can have a long-term negative impact on patient.
The 2024 Scientific Sessions will be held on May 2nd-4th, 2024 in Long Beach, CA. Login to view Sessions and Papers saved as favorites. View…
In a meta-analysis of studies covering more than 400,000 people, climbing stairs was associated with reduced risk for all-cause mortality and death from heart disease.“If…
This randomized clinical trial evaluates clopidogrel monotherapy vs dual antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary interventions who are at high…
Progress has been made in the creation of a new independent Board of Cardiovascular Medicine under the American Board of Medical Specialties, several cardiology societies…
Air pollution accentuates the relationship between poor mental health and premature mortality from heart disease in the United States, researchers reported at ESC Preventive Cardiology…
AbstractAims. To assess use and associations with outcomes of glucagon-like peptide-1 receptor agonists (GLP-1 RA) in a real-world population with heart fa